Earlier this month, Novartis took the shocking step of voluntarily suspending manufacturing of two therapies that use nuclear drugs to focus on and deal with most cancers cells, and likewise halted medical trials for one of many therapies.
On the time, the company explained it was doing so “out of an abundance of warning” so as to “tackle potential high quality points recognized in its manufacturing processes” at amenities in Millburn, N.J., and Ivrea, Italy. No additional rationalization was provided, though a spokesperson did acknowledge regulators cited the corporate final fall for points on the New Jersey plant.
Unlock this text by subscribing to STAT+ and revel in your first 30 days free!
